20.500.12556/DiRROS-27900 Incidence of major adverse cardiovascular events in patients with rheumatoid arthritis treated with Janus kinase inhibitors compared to biologic disease-modifying antirheumatic drugs data from an international collaboration of registries (the "JAK-pot" study) Objective: To assess the incidence of major adverse cardiovascular events (MACE) in RA patients treated with JAKi, TNF-inhibitors (TNFi) or biologic Disease-Modifying Anti-Rheumatic Drugs with other modes of action (bDMARD-OMA) in a multi-country, real-world population. Methods: RA patients from 15 registries in the JAK-pot collaboration were included. MACE incidence was analysed using two approaches: a within-registry analysis aggregating country-specific estimates from registers with >25 incident MACE events through meta-analysis, and an individual-level data combined analysis. We used adjusted linear mixed Poisson regression to obtain incidence rate ratios (IRR) of MACE between treatment groups, accounting for multiple treatment courses. Results: The study included 73'008 treatment courses (16'417 JAKi, 35'373 TNFi and 21'218 bDMARD-OMA) and 828 incident MACE among 51'233 patients. Median follow-up time was 1.3 years, with most of the follow-up concentrated in the first two years of adverse cardiovascular events rheumatoid arthritis patients Janus kinase inhibitors biologic disease-modifying antirheumatic drugs "JAK-pot" study neželeni srčno-žilni dogodki revmatoidni artritis bolniki zaviralci Janus kinaze biološkimi antirevmatiki študija "JAK-pot" true false true Angleški jezik Slovenski jezik Neznano 2026-02-27 09:47:35 2026-02-27 09:47:36 2026-02-28 04:20:53 0000-00-00 00:00:00 2025 0 0 str. 1194-1204 no. 9, [article no.] 43188 Vol. 77 2025 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 616-002 2326-5191 10.1002/art.43188 234984707 RAZ_Aymon_Romain_2025.pdf RAZ_Aymon_Romain_2025.pdf 1 C255AE8A2F5D486FA74C04B61E9E023F fdc29101bc864741a12260a6a7828fb927762bc17f32a59753e26e4552c4e348 28521822-13b9-11f1-8c73-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=41073 https://acrjournals.onlinelibrary.wiley.com/doi/10.1002/art.43188 1 f808e3fa-13b8-11f1-8c73-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=41072 Univerzitetni klinični center Ljubljana 0 0 0